MorphoSys AG has appointed Sung Lee as chief financial officer effective 2 February as it commercialises its first oncology product on the US market. Mr Lee joins from Sangamo Therapeutics Inc where he was CFO. Prior to this, he led global financial planning and analysis at Gilead Sciences Inc. Mr Lee received a master of business taxation from the University of Southern California and a degree in economics from the University of California, Irvine, US.
MorphoSys announced the appointment on 6 January 2021.
Copyright 2021 Evernow Publishing Ltd